申请人:MAP Pharmaceuticals, Inc.
公开号:US20150202198A1
公开(公告)日:2015-07-23
Provided herein are novel cabergoline analogs and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, Parkinson's disease using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the 5-HT
2B
receptor and 5-HT
2C
receptors the using the compounds and compositions disclosed herein.